Telsey Advisory Group analyst Sarang Vora reiterates BRC (NYSE:BRCC) with a Outperform and maintains $8 price target.

U.S. stock futures were mixed this morning, with the Dow futures falling by around 10 points on Monday.

Shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR) shares rose sharply during today’s pre-market trading after the company ...

Citigroup analyst Alexandra Davis maintains BRC (NYSE:BRCC) with a Neutral and raises the price target from $3.5 to $4.75.

Telsey Advisory Group analyst Sarang Vora reiterates BRC (NYSE:BRCC) with a Outperform and maintains $8 price target.

Telsey Advisory Group analyst Sarang Vora reiterates BRC (NYSE:BRCC) with a Outperform and maintains $8 price target.

The company expects continued acceleration of profit and cash flow in 2024 with guidance issued for Adjusted EBITDA of $27.0 mi...